Federated Hermes Inc. lessened its position in Masimo Corporation (NASDAQ:MASI - Free Report) by 3.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 51,002 shares of the medical equipment provider's stock after selling 1,732 shares during the period. Federated Hermes Inc. owned approximately 0.09% of Masimo worth $8,497,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC grew its stake in Masimo by 19.8% during the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock valued at $1,338,509,000 after acquiring an additional 1,340,836 shares in the last quarter. Capital Research Global Investors grew its stake in Masimo by 80.5% during the 4th quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider's stock valued at $405,807,000 after acquiring an additional 1,094,647 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Masimo by 13.4% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,967,838 shares of the medical equipment provider's stock valued at $327,842,000 after acquiring an additional 232,671 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Masimo during the 4th quarter valued at about $33,716,000. Finally, Invesco Ltd. grew its stake in Masimo by 226.4% during the 4th quarter. Invesco Ltd. now owns 277,960 shares of the medical equipment provider's stock valued at $45,947,000 after acquiring an additional 192,802 shares in the last quarter. Institutional investors own 85.96% of the company's stock.
Masimo Price Performance
MASI stock traded up $7.32 during midday trading on Monday, reaching $161.27. 962,017 shares of the company's stock traded hands, compared to its average volume of 549,034. The company has a 50-day simple moving average of $162.89 and a two-hundred day simple moving average of $165.27. Masimo Corporation has a 1-year low of $101.61 and a 1-year high of $194.88. The company has a market cap of $8.74 billion, a price-to-earnings ratio of 30.79 and a beta of 1.21. The company has a quick ratio of 1.62, a current ratio of 2.17 and a debt-to-equity ratio of 0.67.
Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, beating the consensus estimate of $1.24 by $0.12. Masimo had a positive return on equity of 22.56% and a negative net margin of 25.06%. The company had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. During the same period last year, the firm earned $0.77 EPS. The business's revenue for the quarter was down 24.5% on a year-over-year basis. On average, analysts anticipate that Masimo Corporation will post 4.1 earnings per share for the current year.
Insiders Place Their Bets
In other Masimo news, COO Bilal Muhsin sold 10,000 shares of Masimo stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $163.28, for a total transaction of $1,632,800.00. Following the transaction, the chief operating officer owned 24,172 shares of the company's stock, valued at $3,946,804.16. This trade represents a 29.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 16.90% of the company's stock.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on MASI. BTIG Research reaffirmed a "buy" rating on shares of Masimo in a research report on Monday, July 14th. Wells Fargo & Company dropped their target price on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Finally, Raymond James Financial dropped their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $191.60.
View Our Latest Research Report on Masimo
Masimo Profile
(
Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Featured Stories

Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.